Brimonidine 0.33% Topical Gel Brimonidine 0.33% Topical Gel

Brimonidine 0.33% Topical Gel

30 g

This product is indicated for the symptomatic treatment of persistent facial erythema (redness) associated with rosacea in adults aged 18 years and older.

Each 100 g contains:

Brimonidine Tartrate 500 mg, equivalent to Brimonidine 330 mg.

Each 100 g contains:

Brimonidine Tartrate 500 mg, equivalent to Brimonidine 330 mg.

Brimonidine reduces rosacea-associated facial erythema through its local vasoconstrictive effect on the superficial blood vessels of the skin.

This product is a topical gel and is usually applied once daily.

Apply a thin, even layer to the affected areas of the face, typically the forehead, nose, chin, and cheeks.

Avoid contact with the eyes, lips, and mucous membranes. Do not apply to damaged skin.

Wash hands after application.

Brimonidine acts on alpha-2 adrenergic receptors located in the walls of small blood vessels in the skin, causing vasoconstriction. This vasoconstriction reduces superficial cutaneous blood flow and consequently decreases facial erythema associated with vasodilation in rosacea.

Before Use

Use in individuals under 18 years of age is not recommended. This product is contraindicated in children under 2 years of age.

If you are pregnant, breastfeeding, or planning to become pregnant, consult your physician before use.

Consult your physician or pharmacist before use if you have or have previously had any of the following:

Heart problems or circulatory disorders, depression, reduced blood flow to the brain or heart, orthostatic hypotension, reduced blood flow to the extremities, liver or kidney impairment (either currently or in the past), facial laser treatment, a history or planned facial laser treatment

During Use

The maximum recommended daily dose is 1 g of gel, approximately equivalent to 5 pea-sized amounts.

Do not apply more than once daily.

Do not apply the product to irritated skin, including skin following laser treatment, or to open wounds.

Avoid contact with the eyes, lips, inside of the nose, and open wounds.

In some patients, particularly during the first weeks of treatment, temporary worsening of erythema, flushing, or a burning sensation may occur. These reactions generally resolve after discontinuation of treatment.

During the first week of treatment, begin with a smaller amount and gradually increase the amount as needed, up to the maximum recommended dose.

If severe irritation or worsening of erythema occurs, discontinue use and consult your physician.

Contraindications

Children under 2 years of age

Hypersensitivity to brimonidine or any of the ingredients of the product

Store below 30°C, protect from direct sunlight and keep out of the reach of children. Do not freeze.